AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02586896 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening, Assessment, and Referral (SAR)
Description: The research assistant will provide these participants with an information sheet listing treatment (including both specialty treatment centers and primary care clinics that provide buprenorphine) and self-help resources in their community. The referral sheet includes names, addresses, and phone numbers of local addiction treatment agencies. Because the emergency department does not currently screen or refer systematically, the SAR condition represents a level of care significantly higher than treatment as usual. Participants will also receive an informational pamphlet about drug use and its consequences, addiction, and treatment.
Study NCT00089349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given IV
Study NCT00089349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT00089349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given PO
Study NCT03448185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: Subjects will be randomized to the exercise groups will undergo 1 year aerobic exercise training comprised of high intensity exercise sessions 2-3 days per week. Sessions will be supervised remotely via heart rate monitors.
Study NCT03448185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity exercise
Description: Subjects will be randomized to the exercise groups will undergo 1 year aerobic exercise training comprised of high intensity exercise sessions 2-3 days per week. Sessions will be supervised remotely via heart rate monitors.
Study NCT01343732 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep TMS
Description: deep transcranial magnetic stimulation
Study NCT03813992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MED2005
Description: Topical Product
Study NCT04324983 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Additional blood sample of about 30 ml that will be drawn for biomarker analyses (2 EDTA = ethylenediaminetetraacetic acid and 1 Cell-search-tubes).The drawn blood for CTC-Analysis and biomarker identification will be promptly processed ac-cording to the established standards at the Institute for Tumor Biology (see below).~The histological analysis of the resected tissue during salvage surgery is carried out according to clinical routine (conventional haematoxylin and eosin stained and PSMA-Immunohistochemistry). Additionally, tissue samples will undergo molecularpathological analysis if this does not affect routine pathological examination.
Study NCT03040180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy with bleomycin
Description: Systemic injection, once only treatment
Study NCT03813992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MED2005
Description: Topical Product
Study NCT01377870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravenous injection of mesenchymal stem cells
Description: 15 patients with relapsing remitting multiple sclerosis underwent intravenous injection of mesenchymal stem cell
Study NCT01377870 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: injection of cell free media
Description: Patients who are in control group underwent media injection but after 6 months they will be transplanted by stem cell.
Study NCT01807377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: 200 mg tablet administered twice per day for 14 days
Study NCT03040180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoVE
Description: Electroporation using an endoscopic electroporation device
Study NCT02554916 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dual-Belt Exercise
Description: The dual-belted exercise treadmill can control the speeds of the right and left legs individually. When asymmetric, the dual-belt treadmill imposes mechanical and sensory perturbations independently to each leg such that the central nervous system (CNS) must solve and adapt to the challenge to maintain walking.
Study NCT01807377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2mg administered as single doses on Days 0 and 11
Study NCT01807377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered twice per day for 14 days
Study NCT02207959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine Hemisulphate salt
Description: The stomach will be sprayed with 1-10 ml of 0.01% proflavine using a standard endoscopic spray-catheter.
Study NCT02207959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: White-light examination
Description: standard white light examination
Study NCT02207959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging with High Resolution Microendoscope
Description: HRME will be inserted through the biopsy channel of the endoscope, gently placed against the mucosa, and images of suspicious areas will be obtained.
Study NCT00898456 — intervention group
Intervention type: GENETIC
Intervention: gene expression analysis
Study NCT00898456 — intervention group
Intervention type: GENETIC
Intervention: molecular genetic technique
Study NCT00898456 — intervention group
Intervention type: GENETIC
Intervention: polymorphism analysis
Study NCT00898456 — intervention group
Intervention type: GENETIC
Intervention: protein expression analysis
Study NCT02554916 — intervention group
Intervention type: BEHAVIORAL
Intervention: Treadmill Exercise
Description: The treadmill exercise will maintain the speed of the right and left leg together while walking.
Study NCT02554916 — intervention group
Intervention type: OTHER
Intervention: Usual Care
Description: This group will not be assigned to a treadmill but is as a non-exercising control group.
Study NCT02554916 — intervention group
Intervention type: DEVICE
Intervention: Dual-Belt Treadmill
Study NCT00898456 — intervention group
Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Study NCT03561818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-based pulmonary rehabilitation
Description: The patients who undergo two days pulmonary rehabilitation under supervision in our clinic and three days a week at home during two months will taken as hospital group. The exercises include breathing exercises, treadmill (15sc), cycle training (15sc), arm ergometer training (15sc), peripheral muscle training and stretching exercises with free weights.
Study NCT03561818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation
Description: The patients who follow a home-based pulmonary rehabilitation program for two months comprising breathing exercises, training in chest hygiene techniques, peripheral muscle strengthening training and self-walking for 5 days in a week for two months. An exercise follow-up form will give to the patients to record their daily exercises. A similar form will fill by physiotherapist once a week during phone call.
Study NCT03037983 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: rTMS is a non-invasive procedure, in which the administration of a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention will be administered in 20 sessions lasting 50 minutes each over the course of 2-6 weeks. Up to two sessions may be scheduled per day with a one-hour interval in-between.
Study NCT03037983 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Subjects will still attend treatment sessions as outlined in the rTMS intervention. However, the device will not deliver any stimulation to the subject.
Study NCT03845959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD0019 oral capsule
Description: TD0019 are green, hard capsule with size 0, containing yellow herbal powder with special smell of herbal.
Study NCT00765726 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Moroctocog alfa(AF-CC)
Description: Dosing is at the discretion of the investigator during the study
Study NCT00765726 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw for laboratory testing
Description: Hematology and Chemistry panels, Factor VIII inhibitor and recovery studies
Study NCT03091920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1973
Description: Oral Tablet
Study NCT03091920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablet
Study NCT03091920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study NCT04084210 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juul Electronic cigarette
Description: The juul e-cigarette pods contain 0.7 ml nicotine by volume / 5% nicotine by weight.
Study NCT03845959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study NCT01776866 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary Angiography
Description: Coronary angiography include standard coronary angiography (SA) and dual-axis rotational coronary angiography (DARCA). Patient first undergo SA of either left or right coronary system followed by DARCA.
Study NCT00665964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-3 polyethylene
Description: highly cross-linked polyethylene for knee arthroplasty
Study NCT00665964 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N2Vac polethylene
Description: conventional polyethylene
Study NCT02828332 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vineland II (VABS -II)
Description: semi-structured interview with a psychologist; Measure 4 areas: Communication, skills of daily living, socialization and skills Motrices
Study NCT02828332 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality of life
Description: Evaluation of the quality of life and comorbidities
Study NCT03054779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canola Oil
Description: Regular canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
Study NCT03054779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High oleic acid canola oil
Description: High oleic acid canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
Study NCT03054779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western diet oil combination
Description: A typical Western diet fat intake as a control treatment, comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA, will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily
Study NCT03448185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil
Description: Subjects randomized to omega-3 fatty acids will take 2 grams total of omega-3 per day for 1 year.
Study NCT03448185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fish oil
Description: Subjects randomized to omega-3 fatty acids will take 2 grams total of omega-3 per day for 1 year.
Study NCT04084210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Very Low Nicotine Cigarettes
Description: These very low nicotine cigarettes (VLNCs) consist of reduced nicotine cigarettes containing 0.03 mg of nicotine; these VLNCs were obtained from National Institute on Drug Abuse (NIDA's) Drug Supply Program (NOT-DA-14-004).
Study NCT04084210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Nicotine Patch
Description: Active nicotine patches, with dosing based on the package insert (>10 cigs/day = 21 mg patch and \<11 cigs/day = 14 mg patches).
Study NCT04084210 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Active Nicotine Patch
Description: Active nicotine patches, with dosing based on the package insert (>10 cigs/day = 21 mg patch and \<11 cigs/day = 14 mg patches).
Study NCT04084210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Patch
Description: Placebo patch containing no nicotine.
Study NCT00098774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 100 mg/sq m IV infusion q 6 hrs starting 24 hrs after ea MTX dose until serum MTX \< or = 0.05uM Cycles 1-5.
Study NCT04084210 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Patch
Description: Placebo patch containing no nicotine.
Study NCT03448185 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Yoga
Description: Subjects randomized to yoga will undergo yoga training as a control to those randomized to high intensity aerobic exercise.
Study NCT03448185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Subjects randomized to yoga will undergo yoga training as a control to those randomized to high intensity aerobic exercise.
Study NCT03448185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil capsules
Description: Subjects randomized to receive olive oil placebo will take 1 gram total of olive oil capsule per day.
Study NCT03448185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: olive oil capsules
Description: Subjects randomized to receive olive oil placebo will take 1 gram total of olive oil capsule per day.
Study NCT02299557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline gel
Description: Oxymetazoline gel applied intra-anally once daily
Study NCT02299557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel applied intra-anally once daily
Study NCT04227106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EB-101
Description: autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7
Study NCT01500707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900800
Description: SCH 900800, one 20 mg tablet, orally
Study NCT01276093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVI ablation
Description: Pulmonary Vein Ablation using RF.
Study NCT01276093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Amiodarone tablets
Study NCT02617459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobetaxolol eye drops
Description: one drop per time; twice daily
Study NCT03342807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin infusion for subjects in Group Insulin.
Study NCT03342807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aphesis
Description: Aphesis for subjects in Group Aphesis.
Study NCT02505945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Study NCT02505945 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LINX Reflux Management System
Study NCT02827773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Talking Pill Bottle
Description: Made by Talking Rx
Study NCT02218346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG221
Description: AG221 in fed and fasted conditions
Study NCT02539680 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopy
Description: duodenal biopsies
Study NCT00098774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 8 g/sq m IV infusion over 4 hrs Days 1 \& 15 Cycles 1, 2, \& 3; Day 15 Cycle 4 and Day 1 Cycle 5.
Study NCT00098774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 150 mg/sq m PO Days 7-11 Cycles 1-5.
Study NCT02617459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betaxolol eye drops
Description: one drop per time; twice daily
Study NCT03204773 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EuroQol five dimensions questionaire (EQ-5D)
Description: Testing quality of life.
Study NCT02522130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: intracervical injection
Study NCT02522130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral misoprostol
Description: oral treatment
Study NCT02522130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: oral treatment
Study NCT02522130 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral treatment
Study NCT03204773 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Modified Fatigue Impact Scale (MFI)
Description: Screening for fatigue
Study NCT03204773 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brief Pain Inventory (BPI)
Description: Testing for pain
Study NCT04741763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EyePromise Visual Edge
Description: A dietary eye supplement containing 8 mg zeaxanthin and 4 mg lutein and additional proprietary nutrients
Study NCT03204773 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Becks Depression Inventory (BDI)
Description: Screening for depression
Study NCT03204773 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Restless-leg Questionaire (RLS diagnostic criteria)
Description: Testing for restless-legs
Study NCT01921985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
Study NCT01921985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
Study NCT04148976 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A mixture of maltodextrins and calcium caseinate divided into 30g individual packets.
Study NCT04148976 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary portfolio
Description: A mixture of functional foods divided into 30g individual packets.
Study NCT00547885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydrocodeine
Description: Group 1: 2\* 60 mg dihydrocodeine long acting + up to four placebo short action~Group 2: 3\* 60 mg dihydrocodeine long acting + up to six placebo short action~Group 3: 4\* 60 mg dihydrocodeine long acting + up to eight placebo short action~Group 4: 2 placebo for long acting + up to 4\*30 mg dihydrocodeine short acting~Group 5: 3 placebo for long acting + up to 6\*30 mg dihydrocodeine short acting~Group 6: 3 placebo for long acting + up to 8\*30 mg dihydrocodeine short acting
Study NCT04151030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEG placement
Description: Push PEG placement
Study NCT04151030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEG placement
Description: Push PEG placement
Study NCT03956771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real neurofeedback
Description: Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of the participant him/herself. Participants receive feedback of their own brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortical activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.
Study NCT03956771 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham neurofeedback
Description: Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of other participant. Participants receive feedback of other participant' brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortex activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.
Study NCT04741763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EyePromise Visual Edge
Description: A dietary eye supplement containing 8 mg zeaxanthin and 4 mg lutein and additional proprietary nutrients
Study NCT01153698 — intervention group
Intervention type: DRUG
Intervention: dabigatran
Description: anticoagulation
Study NCT01513122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir / ritonavir
Description: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily
Study NCT01513122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-3N(t)RTI
Study NCT01513122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: raltegravir 400mg 1 tablet twice daily.
Study NCT03218930 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed antibiotic prescription
Description: Delayed antibiotic prescription pads will be disseminated to all participating general practitioners in both hard and soft copies.
Study NCT03218930 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Antibiotic prescribing guidelines
Description: Antibiotic prescribing guidelines will be disseminated to all participating general practitioners in both hard and soft copies.